Literature DB >> 10939622

Cholangiocarcinoma and liver cirrhosis in relation to changes due to thioacetamide.

A Al-Bader1, T C Mathew, H Abul, H Al-Sayer, P K Singal, H M Dashti.   

Abstract

Different doses of thioacetamide (0.05%, 0.1% and 0.15%) were used to induce liver cirrhosis in Wistar rats. Thioacetamide at 0.5% caused cirrhosis by the twelfth week of treatment. A severe bile duct proliferation and cholangiocarcinoma was seen at longer intervals. Animals treated with higher doses (0.1% and 0.15%) of thioacetamide developed more severe intense degenerative changes in the liver and died in the twelfth and eighth week respectively. The serum and tissue contents of Zn and Cu changed in a characteristic fashion that was consistent with the severity of the liver damage. Serum Zn and Cu concentrations were at their lowest in the animals that developed severe degenerative liver and died at higher dose (0.15%) of thioacetamide. This study indicates that treatment of rats with 0.05% thiocetamide is more effective and appropriate for the induction of liver cirrhosis. Continued administration of the drug at this dosage led to the development of further changes in the liver. This model may be suitable for studying these long term changes that occur in the liver and lead to cirrhosis. Events that precede the development of severe bile duct proliferation and cholangiocarcinoma may also be studied.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10939622     DOI: 10.1023/a:1007082515548

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  18 in total

1.  The precancerous liver; correlations of histological and biochemical changes in rats during prolonged administration of thioacetamide and butter yellow.

Authors:  H C GRANT; K R REES
Journal:  Proc R Soc Lond B Biol Sci       Date:  1958-01-01

2.  Liver Tumors in Rats Fed Thiourea or Thioacetamide.

Authors:  O G Fitzhugh; A A Nelson
Journal:  Science       Date:  1948-12-03       Impact factor: 47.728

3.  Differential permeabilities of rat renal brush-border and basolateral membrane vesicles.

Authors:  M S Lipkowitz; R G Abramson
Journal:  Am J Physiol       Date:  1989-01

4.  Alterations of trace elements in kidney, spleen and lungs in treated and untreated experimental liver cirrhosis.

Authors:  H Dashti; A Behbehani; H Abul; T Hussain; P Madda
Journal:  J R Coll Surg Edinb       Date:  1995-06

5.  Rapid development of hyperplastic nodules and cirrhosis in the liver of rats treated concurrently with thioacetamide and the pyrrolizidine alkaloid lasiocarpine.

Authors:  J K Reddy; M S Rao; M V Jago
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

6.  Selenium and liver cirrhosis.

Authors:  A Al-Bader; H Abul; T Hussain; M Al-Moosawi; T C Mathew; H Dashti
Journal:  Mol Cell Biochem       Date:  1998-08       Impact factor: 3.396

7.  Thioacetamide- and carbon tetrachloride-induced liver cirrhosis.

Authors:  H Dashti; B Jeppsson; I Hägerstrand; B Hultberg; U Srinivas; M Abdulla; S Bengmark
Journal:  Eur Surg Res       Date:  1989       Impact factor: 1.745

8.  Glutathione peroxidase activity in bovine serum and erythrocytes in relation to selenium concentrations of blood, serum and liver.

Authors:  K G Thompson; A J Fraser; B M Harrop; J A Kirk
Journal:  Res Vet Sci       Date:  1980-05       Impact factor: 2.534

Review 9.  Zinc: an overview.

Authors:  A S Prasad
Journal:  Nutrition       Date:  1995 Jan-Feb       Impact factor: 4.008

10.  Tissue repair response as a function of dose in thioacetamide hepatotoxicity.

Authors:  R S Mangipudy; S Chanda; H M Mehendale
Journal:  Environ Health Perspect       Date:  1995-03       Impact factor: 9.031

View more
  9 in total

1.  Hepatic injury due to combined choline-deprivation and thioacetamide administration: an experimental approach to liver diseases.

Authors:  Hussam Al-Humadi; Stamatios Theocharis; Ismene Dontas; Vasileios Stolakis; Apostolos Zarros; Argyro Kyriakaki; Rafal Al-Saigh; Charis Liapi
Journal:  Dig Dis Sci       Date:  2012-07-10       Impact factor: 3.199

Review 2.  Animal models of cholangiocarcinoma.

Authors:  Emilien Loeuillard; Samantha R Fischbach; Gregory J Gores; Sumera Rizvi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-05       Impact factor: 5.187

3.  Comprehensive characterization of serum clinical chemistry parameters and the identification of urinary superoxide dismutase in a carbon tetrachloride-induced model of hepatic fibrosis in the female Hanover Wistar rat.

Authors:  Rosemary Smyth; Michael R Munday; Malcolm J York; Christopher J Clarke; Theo Dare; John A Turton
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

4.  Leptin enhances cholangiocarcinoma cell growth.

Authors:  Giammarco Fava; Gianfranco Alpini; Chiara Rychlicki; Stefania Saccomanno; Sharon DeMorrow; Luciano Trozzi; Cinzia Candelaresi; Julie Venter; Antonio Di Sario; Marco Marzioni; Italo Bearzi; Shannon Glaser; Domenico Alvaro; Luca Marucci; Heather Francis; Gianluca Svegliati-Baroni; Antonio Benedetti
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

Review 5.  Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma.

Authors:  Samuele De Minicis; Tatiana Kisseleva; Heather Francis; Gianluca Svegliati Baroni; Antonio Benedetti; David Brenner; Domenico Alvaro; Gianfranco Alpini; Marco Marzioni
Journal:  Dig Liver Dis       Date:  2012-11-22       Impact factor: 4.088

6.  Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma.

Authors:  Yi-Yin Jan; Ta-Sen Yeh; Jun-Nan Yeh; Horng-Ren Yang; Miin-Fu Chen
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

7.  Integration of Adverse Outcome Pathways, Causal Networks and 'Omics to Support Chemical Hazard Assessment.

Authors:  Edward J Perkins; E Alice Woolard; Natàlia Garcia-Reyero
Journal:  Front Toxicol       Date:  2022-03-24

Review 8.  Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research.

Authors:  Man Li; Xueli Zhou; Wei Wang; Baoan Ji; Yu Shao; Qianyu Du; Jinghao Yao; Yan Yang
Journal:  J Clin Transl Hepatol       Date:  2022-02-11

9.  Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats.

Authors:  Hong Ling; Eric Roux; Donna Hempel; Jingzang Tao; Mandy Smith; Scott Lonning; Anna Zuk; Cynthia Arbeeny; Steve Ledbetter
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.